Dr Janet Graham
- Honorary Clinical Associate Professor (School of Cancer Sciences)
email:
Janet.Graham@glasgow.ac.uk
Centre for Oncology & Applied, Pharmacology, Beatson Laboratories, Garscube Estate
Publications
2024
Purdie, C., Clark, G. R.C., Cameron, D. A., Petty, R., Mariappan, P., Graham, J., Burton, K. A. and Morrison, D. S. (2024) Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: a population-based study of 154,863 patients. Journal of Cancer Policy, 42, 100502. (doi: 10.1016/j.jcpo.2024.100502) (PMID:39243812)
Shiu, K.-K. et al. (2024) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31 May-04 June 2024. (doi: 10.1200/jco.2024.42.17_suppl.lba3504)
Solheim, T. S. et al. (2024) Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31 May-04 June 2024. (doi: 10.1200/jco.2024.42.17_suppl.lba12007)
Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)
2023
Van Cutsem, E. et al. (2023) ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. Journal of Clinical Oncology, 41(14), pp. 2628-2637. (doi: 10.1200/JCO.22.01693) (PMID:36763936)
2022
Brown, L. C. et al. (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19(2), pp. 146-157. (doi: 10.1177/17407745211069879) (PMID:35083924) (PMCID:PMC9036145)
Mueller, T. et al. (2022) Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 28(1), p. 14604582221077055. (doi: 10.1177/14604582221077055) (PMID:35195024)
2021
Adams, R. A. et al. (2021) Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology, 39(33), pp. 3693-3704. (doi: 10.1200/JCO.21.01436) (PMID:34516759)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
Haq, M. I. et al. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10(13), 2770. (doi: 10.3390/jcm10132770) (PMID:34202593) (PMCID:PMC8269358)
Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)
Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)
Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)
2020
Roseweir, A. K. et al. (2020) Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 6(4), pp. 283-296. (doi: 10.1002/cjp2.171) (PMID:32401426) (PMCID:PMC7578335)
Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, 4748. (doi: 10.1038/s41467-020-18151-y) (PMID:32958763) (PMCID:PMC7505971)
Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)
Park, J. H. , Fuglestad, A. J., Køstner, A. H., Oliwa, A., Graham, J., Horgan, P. G. , Roxburgh, C. S.D. , Kersten, C. and McMillan, D. C. (2020) Systemic inflammation and outcome in 2295 patients with stage I-III colorectal cancer from Scotland and Norway: First results from the ScotScan Colorectal Cancer Group. Annals of Surgical Oncology, 27, pp. 2784-2794. (doi: 10.1245/s10434-020-08268-1) (PMID:32248375) (PMCID:PMC7334267)
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, et al. (2020) Pan-cancer analysis of whole genomes. Nature, 578(7793), pp. 82-93. (doi: 10.1038/s41586-020-1969-6) (PMID:32025007) (PMCID:PMC7025898)
2019
Derby, S. , Graham, J. and McIntosh, D. (2019) An unusual cause of paraesthesia in a neo-adjuvant gastro-oesophageal cancer. BMJ Case Reports, 12(8), e225450. (doi: 10.1136/bcr-2018-225450) (PMID:31444258) (PMCID:PMC6721004)
Bouttell, J. , Tan, Y. Y., Creed, D., McGaffin, G., Hawkins, N. , McLaughlin, R., Smith, G., Westwood, P., Williams, N. and Graham, J. (2019) Context-specific economic evaluation for molecular pathology tests: An application in colorectal cancer in the West of Scotland. International Journal of Technology Assessment in Health Care, 35(4), pp. 327-333. (doi: 10.1017/S026646231900045X) (PMID:31292015)
2018
Palmer, D. H. et al. (2018) A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer, 118(9), pp. 1162-1168. (doi: 10.1038/s41416-018-0051-8) (PMID:29563636) (PMCID:PMC5943284)
2017
Graham, J., Spiliopoulou, P. , Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)
Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi: 10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)
Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)
2016
Graham, J.S., Boyd, K. , Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, 161. (doi: 10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)
Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)
2015
Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi: 10.1111/cge.12536) (PMID:25388820)
Omlin, A. et al. (2015) AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 33(3), pp. 679-690. (doi: 10.1007/s10637-015-0235-5) (PMID:25920479)
Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)
2014
Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi: 10.1186/1472-6890-14-35)
2013
Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)
Pinato, D.J., Graham, J., Gabra, H. and Sharma, R. (2013) Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews, 39(2), pp. 153-160. (doi: 10.1016/j.ctrv.2012.04.004)
2012
Graham, J.S. and Cassidy, J. (2012) Adjuvant therapy in colon cancer. Expert Review of Anticancer Therapy, 12(1), pp. 99-109. (doi: 10.1586/era.11.189)
2011
Sharma, R., Graham, J., Blagden, S. and Gabra, H. (2011) Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer. BMC Cancer, 11(1), p. 289. (doi: 10.1186/1471-2407-11-289)
Articles
Purdie, C., Clark, G. R.C., Cameron, D. A., Petty, R., Mariappan, P., Graham, J., Burton, K. A. and Morrison, D. S. (2024) Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: a population-based study of 154,863 patients. Journal of Cancer Policy, 42, 100502. (doi: 10.1016/j.jcpo.2024.100502) (PMID:39243812)
Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)
Van Cutsem, E. et al. (2023) ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. Journal of Clinical Oncology, 41(14), pp. 2628-2637. (doi: 10.1200/JCO.22.01693) (PMID:36763936)
Brown, L. C. et al. (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19(2), pp. 146-157. (doi: 10.1177/17407745211069879) (PMID:35083924) (PMCID:PMC9036145)
Mueller, T. et al. (2022) Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 28(1), p. 14604582221077055. (doi: 10.1177/14604582221077055) (PMID:35195024)
Adams, R. A. et al. (2021) Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology, 39(33), pp. 3693-3704. (doi: 10.1200/JCO.21.01436) (PMID:34516759)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
Haq, M. I. et al. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10(13), 2770. (doi: 10.3390/jcm10132770) (PMID:34202593) (PMCID:PMC8269358)
Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)
Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)
Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)
Roseweir, A. K. et al. (2020) Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 6(4), pp. 283-296. (doi: 10.1002/cjp2.171) (PMID:32401426) (PMCID:PMC7578335)
Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, 4748. (doi: 10.1038/s41467-020-18151-y) (PMID:32958763) (PMCID:PMC7505971)
Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)
Park, J. H. , Fuglestad, A. J., Køstner, A. H., Oliwa, A., Graham, J., Horgan, P. G. , Roxburgh, C. S.D. , Kersten, C. and McMillan, D. C. (2020) Systemic inflammation and outcome in 2295 patients with stage I-III colorectal cancer from Scotland and Norway: First results from the ScotScan Colorectal Cancer Group. Annals of Surgical Oncology, 27, pp. 2784-2794. (doi: 10.1245/s10434-020-08268-1) (PMID:32248375) (PMCID:PMC7334267)
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, et al. (2020) Pan-cancer analysis of whole genomes. Nature, 578(7793), pp. 82-93. (doi: 10.1038/s41586-020-1969-6) (PMID:32025007) (PMCID:PMC7025898)
Derby, S. , Graham, J. and McIntosh, D. (2019) An unusual cause of paraesthesia in a neo-adjuvant gastro-oesophageal cancer. BMJ Case Reports, 12(8), e225450. (doi: 10.1136/bcr-2018-225450) (PMID:31444258) (PMCID:PMC6721004)
Bouttell, J. , Tan, Y. Y., Creed, D., McGaffin, G., Hawkins, N. , McLaughlin, R., Smith, G., Westwood, P., Williams, N. and Graham, J. (2019) Context-specific economic evaluation for molecular pathology tests: An application in colorectal cancer in the West of Scotland. International Journal of Technology Assessment in Health Care, 35(4), pp. 327-333. (doi: 10.1017/S026646231900045X) (PMID:31292015)
Palmer, D. H. et al. (2018) A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer, 118(9), pp. 1162-1168. (doi: 10.1038/s41416-018-0051-8) (PMID:29563636) (PMCID:PMC5943284)
Graham, J., Spiliopoulou, P. , Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)
Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi: 10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)
Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)
Graham, J.S., Boyd, K. , Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, 161. (doi: 10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)
Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)
Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi: 10.1111/cge.12536) (PMID:25388820)
Omlin, A. et al. (2015) AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 33(3), pp. 679-690. (doi: 10.1007/s10637-015-0235-5) (PMID:25920479)
Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)
Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi: 10.1186/1472-6890-14-35)
Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)
Pinato, D.J., Graham, J., Gabra, H. and Sharma, R. (2013) Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews, 39(2), pp. 153-160. (doi: 10.1016/j.ctrv.2012.04.004)
Graham, J.S. and Cassidy, J. (2012) Adjuvant therapy in colon cancer. Expert Review of Anticancer Therapy, 12(1), pp. 99-109. (doi: 10.1586/era.11.189)
Sharma, R., Graham, J., Blagden, S. and Gabra, H. (2011) Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer. BMC Cancer, 11(1), p. 289. (doi: 10.1186/1471-2407-11-289)
Conference or Workshop Item
Shiu, K.-K. et al. (2024) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31 May-04 June 2024. (doi: 10.1200/jco.2024.42.17_suppl.lba3504)
Solheim, T. S. et al. (2024) Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31 May-04 June 2024. (doi: 10.1200/jco.2024.42.17_suppl.lba12007)